Aerovate Therapeutics
Boston
About Aerovate Therapeutics
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $72.6M
- Funding stage: M&A
- Last round: Series A (Aug 2020)
- Ticker: nasdaq:AVTE
- Website: aerovatetx.com
- Phone: +1 617 778 2494
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/aerovate-therapeutics-26470 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.